Table 1.
Baseline demographic and disease characteristics of patients included in the analysis.
| Characteristics | Mean (S.D) |
|---|---|
| Age, years | 58 (9.5) |
| Gender, % male/%female | 53/47 |
| ECOG | 0–1 |
| Weight, kg | 72.2 (16.2) |
| Height, cm | 164.4 (13.2) |
| BMI | 27.2 (5.7) |
| BSA, m2 | 1.78 (0.4) |
| Total daily dose, mg/m2 | 1265 (3 5 0) |
| Serum creatinine, μmol/l | 61 (25.9) |
| CrCl, mL/min | 102 (33.5) |
| Albumin concentration, g/l | 32.9 (7.6) |
| AST, IU/l | 24 (10.2) |
| ALT, IU/l | 22.6 (21.5) |
| Direct Bilirubin, μmol/l | 2.89 (1.3) |
| WBC, x109/l | 5.6 (2.5) |
| Hb, g/l | 122.5 (18.8) |
| Platelet, x109/l | 226 (1 0 0) |
| Disease stage, n (%) | |
| Stage I and II | 5 (16.6%) |
| Stage III | 7 (23.3%) |
| Stage IV | 18 (60%) |
| Other drugs | |
| Oxaliplatin | 9 (30%) |
| Bevacizumab | 7 (23%) |
| Irinotecan | 3 (10%) |